Sodium –glucose co‐transporter 2 inhibitors: ‘a tale of two sisters’, diabetes and heart failure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 14, 2020 Category: Cardiology Authors: Dimitrios Farmakis, Javed Butler, Gerasimos Filippatos Tags: Editorial Comment Source Type: research

Management of heart failure patients with COVID ‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association of the European Society of Cardiology
AbstractThe coronavirus disease 2019 (COVID ‐19) pandemic of severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) infection is causing considerable morbidity and mortality worldwide. Multiple reports have suggested that patients with heart failure (HF) are at a higher risk of severe disease and mortality with COVID‐19. Moreove r, evaluating and treating HF patients with comorbid COVID‐19 represents aformidable clinical challenge as symptoms of both conditions may overlap and they may potentiate each other. Limited data exist regarding comprehensive management of HF patients with concomitant COVID ‐19. S...
Source: European Journal of Heart Failure - July 13, 2020 Category: Cardiology Authors: Yuhui Zhang, Andrew J.S. Coats, Zhe Zheng, Marianna Adamo, Giuseppe Ambrosio, Stefan D. Anker, Javed Butler, Dingli Xu, Jingyuan Mao, Muhammad Shahzeb Khan, Ling Bai, Alexandre Mebazaa, Piotr Ponikowski, Qizhu Tang, Frank Ruschitzka, Petar Tags: Position Paper Source Type: research

Cardiovascular magnetic resonance in heart failure with preserved ejection fraction: myocyte, interstitium, microvascular, and metabolic abnormalities
AbstractHeart failure (HF) with preserved ejection fraction (HFpEF) is a chronic cardiac condition whose prevalence continues to rise, with high social and economic burden, but with no specific approved treatment. Patients diagnosed with HFpEF have a high prevalence of comorbidities and there is a likely high misdiagnosis rate. True HFpEF is likely to have multiple pathophysiological causes – with these causes themselves clinically ill‐defined through limitations of current measurement techniques. Myocyte, interstitium, microvascular, and metabolic abnormalities have been regarded as key components of the pathophys...
Source: European Journal of Heart Failure - July 12, 2020 Category: Cardiology Authors: Giovanni Quarta, Mauro Gori, Annamaria Iorio, Emilia D'Elia, James C Moon, Attilio Iacovoni, Simone Burocchi, Erik B Schelbert, Paolo Brambilla, Sandro Sironi, Sergio Caravita, Gianfranco Parati, Antonello Gavazzi, Alan S Maisel, Javed Butle Tags: Review Source Type: research

An Expert Consensus Document on the Management of Cardiovascular Manifestations of Fabry Disease
AbstractFabry disease (FD) is an X ‐linked lysosomal storage disorder caused by pathogenic variants in the α‐galactosidase A gene (GLA) that leads to reduced or undetectable α‐galactosidase A (AGAL‐A) enzyme activity and progressive accumulation of globotriaosylceramide (Gb3) and its deacylated form globotriaosylsphingosine (lysoGb3) in cells throughout the body. FD can be multisystemic with neurological, renal, cutaneous and cardiac involvement or be limited to the heart.Cardiac involvement is characterized by progressive cardiac hypertrophy, fibrosis, arrhythmias, heart failure and sudden cardiac deat...
Source: European Journal of Heart Failure - July 8, 2020 Category: Cardiology Authors: Ale š Linhart, Dominique P. Germain, Iacopo Olivotto, Mohammed M. Akhtar, Aris Anastasakis, Derralynn Hughes, Mehdi Namdar, Maurizio Pieroni, Albert Hagège, Franco Cecchi, Juan R Gimeno, Giuseppe Limongelli, Perry Elliott Tags: Position Paper Source Type: research

Angiotensin ‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust
AbstractAimsThe SARS ‐CoV‐2 virus binds to the angiotensin‐converting enzyme 2 (ACE2) receptor for cell entry. It has been suggested that angiotensin‐converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARB), which are commonly used in patients with hypertension or diabetes and may raise tis sue ACE2 levels, could increase the risk of severe COVID‐19 infection.Methods and resultsWe evaluated this hypothesis in a consecutive cohort of 1200 acute inpatients with COVID ‐19 at two hospitals with a multi‐ethnic catchment population in London (UK). The mean age was 68 ± 17&...
Source: European Journal of Heart Failure - July 7, 2020 Category: Cardiology Authors: Daniel M. Bean, Zeljko Kraljevic, Thomas Searle, Rebecca Bendayan, O'Gallagher Kevin, Andrew Pickles, Amos Folarin, Lukasz Roguski, Kawsar Noor, Anthony Shek, Rosita Zakeri, Ajay M. Shah, James T.H. Teo, Richard J.B. Dobson Tags: Research Article Source Type: research

All rise! Orthostatic hypotension in heart failure: reply
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 7, 2020 Category: Cardiology Authors: Jean ‐Michel Tartiere, Alain Cohen‐Solal, François Roubille, Nicolas Girerd, Jennifer Cautela Tags: Letter to the Editor Source Type: research

Heart failure ‐related hospitalisation and management during the COVID‐19 pandemic: a reflection
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 7, 2020 Category: Cardiology Authors: Nisa Shah, Irfan Ahmed, Tahir Nazir Tags: Letter to the Editor Source Type: research

Secrets of Spironolactone: Continuing Insights from TOPCAT Americas
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 6, 2020 Category: Cardiology Authors: Andreas P. Kalogeropoulos, Panagiotis Simitsis, Hal A. Skopicki Tags: Editorial Comment Source Type: research

Association Between HbA1c Levels and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Cardiovascular Disease: A Secondary Analysis of the TECOS Randomized Clinical Trial
ConclusionHbA1c exhibits a U ‐shaped association with cardiovascular outcomes in patients with T2D and atherosclerotic vascular disease, with nadir around 7%.This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2020 Category: Cardiology Authors: Finlay A. McAlister, Yinggan Zheng, Cynthia M. Westerhout, John B. Buse, Eberhard Standl, Darren K. McGuire, Frans Van de Werf, Jennifer B. Green, Paul W. Armstrong, Rury R. Holman, on behalf of the TECOS Study Group Tags: Research Article Source Type: research

The role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a Position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio ‐Oncology Council of the European Society of Cardiology (ESC)
This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2020 Category: Cardiology Authors: Jelena Čelutkienė, Radek Pudil, Teresa López‐Fernández, Julia Grapsa, Petros Nihoyannopoulos, Jutta Bergler‐Klein, Alain Cohen‐Solal, Dimitrios Farmakis, Carlo Gabriele Tocchetti, Stephan Haehling, Vassilis Barberis, Frank A. Flachska Tags: Position Paper Source Type: research

Regional Adiposity and Heart Failure with Preserved Ejection Fraction
This article is protected by copyright. All rights reserved. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 3, 2020 Category: Cardiology Authors: Vishal N. Rao, Marat Fudim, Robert J. Mentz, Erin D. Michos, G. Michael Felker Tags: Research Article Source Type: research

Young patients with heart failure – clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers
AbstractAimsThe prevalence and hospitalizations of patients with heart failure (HF) aged
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: C Basic, A Rosengren, U Alehagen, U Dahlstr öm, M Edner, M Fu, M Novak, T Zverkova Sandström, M Schaufelberger Tags: Research Article Source Type: research

Long ‐term outcome and its predictors in giant cell myocarditis
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Kaj Ekstr öm, Anne Räisänen‐Sokolowski, Jukka Lehtonen, Markku Kupari Tags: Letter to the Editor Source Type: research

Decreases in acute heart failure hospitalizations during COVID ‐19
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Zachary L. Cox, Pikki Lai, JoAnn Lindenfeld Tags: Viewpoint Source Type: research

Hospitalizations for Heart Failure During the COVID ‐19 Pandemic Making Sense of the Known Knowns, Known Unknowns, and the Unknown Unknowns
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Andrew P. Ambrosy, Jesse K. Fitzpatrick, Marat Fudim Tags: Editorial Comment Source Type: research

Sodium glucose co ‐transporter‐2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology
ABSTRACTHeart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium ‐glucose co‐transporter 2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) have demonstrated beneficial effects for three SGLT‐2) inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from CV causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without T2DM. A number of additiona...
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Petar M. Seferovi ć, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Tags: Position Paper Source Type: research

Decreases in acute heart failure hospitalizations during COVID ‐19
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Zachary L. Cox, Pikki Lai, JoAnn Lindenfeld Tags: Viewpoint Source Type: research

Hospitalizations for Heart Failure During the COVID ‐19 Pandemic Making Sense of the Known Knowns, Known Unknowns, and the Unknown Unknowns
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Andrew P. Ambrosy, Jesse K. Fitzpatrick, Marat Fudim Tags: Editorial Comment Source Type: research

Sodium glucose co ‐transporter‐2 inhibitors in heart failure: beyond glycaemic control. The Position Paper of the Heart Failure Association of the European Society of Cardiology
ABSTRACTHeart failure (HF) is common and associated with a poor prognosis, despite advances in treatment. Over the last decade cardiovascular outcome trials with sodium ‐glucose co‐transporter 2 (SGLT‐2) inhibitors in patients with type 2 diabetes mellitus (T2DM) have demonstrated beneficial effects for three SGLT‐2) inhibitors (empagliflozin, canagliflozin and dapagliflozin) in reducing hospitalisations for HF. More recently, dapagliflozin reduced the risk of worsening HF or death from CV causes in patients with chronic HF with reduced left ventricular ejection fraction, with or without T2DM. A number of additiona...
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Petar M. Seferovi ć, Gabriele Fragasso, Mark Petrie, Wilfried Mullens, Roberto Ferrari, Thomas Thum, Johann Bauersachs, Stefan D. Anker, Robin Ray, Yuksel Çavuşoğlu, Marija Polovina, Marco Metra, Giuseppe Ambrosio, Krishna Prasad, Jelena Tags: Position Paper Source Type: research

Young patients with heart failure – clinical characteristics and outcomes. Data from the Swedish Heart Failure, National Patient, Population and Cause of Death Registers
AbstractAimsThe prevalence and hospitalizations of patients with heart failure (HF) aged
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: C Basic, A Rosengren, U Alehagen, U Dahlstr öm, M Edner, M Fu, M Novak, T Zverkova Sandström, M Schaufelberger Tags: Research Article Source Type: research

Long ‐term outcome and its predictors in giant cell myocarditis
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 2, 2020 Category: Cardiology Authors: Kaj Ekstr öm, Anne Räisänen‐Sokolowski, Jukka Lehtonen, Markku Kupari Tags: Letter to the Editor Source Type: research

Care for patients with ventricular assist devices and suspected COVID ‐19 infection
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 1, 2020 Category: Cardiology Authors: Andrew Xanthopoulos, Filippos Triposkiadis, Randall C. Starling Tags: Viewpoint Source Type: research

Looking at the heart failure through the prism of liver dysfunction
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Robert Zymli ński, Piotr Ponikowski, Jan Biegus Tags: Editorial Comment Source Type: research

Do Cheyne and Stokes have an important message for modern ‐day patients with heart failure? Yes, they do
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Massimo F. Piepoli, Piotr P. Ponikowski, Maurizio Volterrani, Darrel P. Francis, Andrew J.S. Coats Tags: Editorial Comment Source Type: research

Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Puja B. Parikh, Grigorios Tsigkas, Andreas P. Kalogeropoulos Tags: Editorial Comment Source Type: research

Right ‐sided cardiac disease: no longer the ‘dark side of the heart’
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Thomas M. Gorter, Dirk J. Veldhuisen, Michael G. Dickinson Tags: Editorial Comment Source Type: research

Do Cheyne and Stokes have an important message for modern ‐day patients with heart failure? Yes, they do
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Massimo F. Piepoli, Piotr P. Ponikowski, Maurizio Volterrani, Darrel P. Francis, Andrew J.S. Coats Tags: Editorial Comment Source Type: research

Transcatheter aortic valve replacement after heart failure hospitalization: too little, too late?
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Puja B. Parikh, Grigorios Tsigkas, Andreas P. Kalogeropoulos Tags: Editorial Comment Source Type: research

Right ‐sided cardiac disease: no longer the ‘dark side of the heart’
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 30, 2020 Category: Cardiology Authors: Thomas M. Gorter, Dirk J. Veldhuisen, Michael G. Dickinson Tags: Editorial Comment Source Type: research

Practice makes perfect: improved long ‐term survival in nonischaemic dilated cardiomyopathy with contemporary treatment
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 29, 2020 Category: Cardiology Authors: Petar M Seferovi ć, Milika Ašanin, Marija Polovina Tags: Editorial Comment Source Type: research

Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review
ConclusionThe majority of current diagnostic HFpEF biomarker studies have a high risk of bias, reducing the reproducibility and the potential for clinical care. Methodological well ‐designed studies with a uniform reference diagnosis are urgently needed to determine the incremental value of circulating biomarkers for the diagnosis of HFpEF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: M.T.H.M. Henkens, S. Remmelzwaal, E.L. Robinson, A.J. van Ballegooijen, M.A. Barandiar án Aizpurua, J.A.J. Verdonschot, A.G. Raafs, J. Weerts, M.R. Hazebroek, S. van Sanders‐Wijk, M.L. Handoko, H.M. Ruijter, C.S.P. Lam, R.A. Boer, W.J. Pa Tags: Research Article Source Type: research

What should the C ( “Congestive heart failure”) represent in the CHA2DS2‐VASc score?
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Bart A. Mulder, Dirk J. Veldhuisen, Michiel Rienstra Tags: Viewpoint Source Type: research

Pulmonary artery pressure ‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF)
ABSTRACTAimsHeart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP) ‐guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS Eu ropean Monitoring Study for Heart Failure (MEMS‐HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland.Methods and results234...
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Christiane E. Angermann, Birgit Assmus, Stefan D. Anker, Folkert W. Asselbergs, Johannes Brachmann, Marie ‐Elena Brett, Jasper J. Brugts, Georg Ertl, Greg Ginn, Lutz Hilker, Friedrich Koehler, Stephan Rosenkranz, Qian Zhou, Philip B. Adamso Tags: Research Article Source Type: research

The dilemma of renin –angiotensin system inhibitors in coronavirus disease 2019 (COVID‐19): insights into lung fluid handling and gas exchange in heart failure patients
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Marco Guazzi, Alice Moroni Tags: Viewpoint Source Type: research

Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction
We examined temporal changes in LV structures and their prognostic impacts during a median 8.7‐year follow‐up. From (‐)LVH/(‐)LVE, (+)LVH/(‐)LVE to (+)LVH/(+)LVE at baseline, the incidence for the primary outcome, a composite of cardiovascular death or HF admission, significantly increased. Among 1,808 patients who under went echocardiography at both baseline and 1‐year, we noted substantial group transitions from baseline to 1‐year; the transition rates from (‐)LVH/(‐)LVE to (+)LVH/(‐)LVE, from (+)LVH/(‐)LVE to (‐)LVH/(‐)LVE, from (+)LVH/(‐)LVE to (+)LVH/(+)LVE, and from (+)LVH/(+)LVE to (+)LVH...
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Shinsuke Yamanaka, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa, Tags: Research Article Source Type: research

Risk of bias in studies investigating novel diagnostic biomarkers for Heart Failure with Preserved Ejection Fraction. A systematic review
ConclusionThe majority of current diagnostic HFpEF biomarker studies have a high risk of bias, reducing the reproducibility and the potential for clinical care. Methodological well ‐designed studies with a uniform reference diagnosis are urgently needed to determine the incremental value of circulating biomarkers for the diagnosis of HFpEF. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: M.T.H.M. Henkens, S. Remmelzwaal, E.L. Robinson, A.J. van Ballegooijen, M.A. Barandiar án Aizpurua, J.A.J. Verdonschot, A.G. Raafs, J. Weerts, M.R. Hazebroek, S. van Sanders‐Wijk, M.L. Handoko, H.M. Ruijter, C.S.P. Lam, R.A. Boer, W.J. Pa Tags: Research Article Source Type: research

The dilemma of renin –angiotensin system inhibitors in coronavirus disease 2019 (COVID‐19): insights into lung fluid handling and gas exchange in heart failure patients
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Marco Guazzi, Alice Moroni Tags: Viewpoint Source Type: research

Prognostic impacts of dynamic cardiac structural changes in heart failure patients with preserved left ventricular ejection fraction
We examined temporal changes in LV structures and their prognostic impacts during a median 8.7‐year follow‐up. From (‐)LVH/(‐)LVE, (+)LVH/(‐)LVE to (+)LVH/(+)LVE at baseline, the incidence for the primary outcome, a composite of cardiovascular death or HF admission, significantly increased. Among 1,808 patients who under went echocardiography at both baseline and 1‐year, we noted substantial group transitions from baseline to 1‐year; the transition rates from (‐)LVH/(‐)LVE to (+)LVH/(‐)LVE, from (+)LVH/(‐)LVE to (‐)LVH/(‐)LVE, from (+)LVH/(‐)LVE to (+)LVH/(+)LVE, and from (+)LVH/(+)LVE to (+)LVH...
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Shinsuke Yamanaka, Yasuhiko Sakata, Kotaro Nochioka, Masanobu Miura, Shintaro Kasahara, Masayuki Sato, Hajime Aoyanagi, Takahide Fujihashi, Hideka Hayashi, Takashi Shiroto, Koichiro Sugimura, Jun Takahashi, Satoshi Miyata, Hiroaki Shimokawa, Tags: Research Article Source Type: research

Pulmonary artery pressure ‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS‐HF)
ABSTRACTAimsHeart failure (HF) leads to repeat hospitalisations and reduces the duration and quality of life. Pulmonary artery pressure (PAP) ‐guided HF management using the CardioMEMS™ HF system was shown to be safe and reduce HF hospitalisation (HFH) rates in New York Heart Association (NYHA) class III patients. However, these findings have not been replicated in health systems outside the United States. Therefore, the CardioMEMS Eu ropean Monitoring Study for Heart Failure (MEMS‐HF) evaluated the safety, feasibility, and performance of this device in Germany, The Netherlands, and Ireland.Methods and results234...
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Christiane E. Angermann, Birgit Assmus, Stefan D. Anker, Folkert W. Asselbergs, Johannes Brachmann, Marie ‐Elena Brett, Jasper J. Brugts, Georg Ertl, Greg Ginn, Lutz Hilker, Friedrich Koehler, Stephan Rosenkranz, Qian Zhou, Philip B. Adamso Tags: Research Article Source Type: research

What should the C ( “Congestive heart failure”) represent in the CHA2DS2‐VASc score?
European Journal of Heart Failure, Accepted Article. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 27, 2020 Category: Cardiology Authors: Bart A. Mulder, Dirk J. Veldhuisen, Michiel Rienstra Tags: Viewpoint Source Type: research

Contemporary survival trends and aetiological characterization in non ‐ischaemic dilated cardiomyopathy
AbstractAimContemporary survival trends in dilated cardiomyopathy (DCM) are largely unknown. The aim of this study is to investigate clinical descriptors, survival trends and the prognostic impact of aetiological characterization in DCM patients.Methods and resultsDilated cardiomyopathy patients were consecutively enrolled and divided into four groups according to the period of enrolment (1978 –1984; 1985–1994; 1995–2004; and 2005–2015). A subset of patients with DCM of specific aetiology, enrolled from 2005 to 2015, was also analysed. Over a mean follow‐up of 12 ± 8 ye...
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Marco Merlo, Antonio Cannat à, Carola Pio Loco, Davide Stolfo, Giulia Barbati, Jessica Artico, Piero Gentile, Valerio De Paris, Federica Ramani, Massimo Zecchin, Marta Gigli, Bruno Pinamonti, Renata Korcova, Andrea Di Lenarda, Mauro Giacca, Tags: Research Article Source Type: research

Characterization of the inflammatory ‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
AbstractAccumulating evidence points to the existence of an inflammatory ‐metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal‐to‐mildly increased left ventricular volumes and systolic blood pres sures, and possibly, altered activity of adipocyte‐associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders – e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthriti...
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Milton Packer, Carolyn S.P. Lam, Lars H. Lund, Mathew S. Maurer, Barry A. Borlaug Tags: Review Source Type: research

Experience of remote cardiac care during the COVID ‐19 pandemic: the V‐LAP™ device in advanced heart failure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Domenico D'Amario, Attilio Restivo, Francesco Canonico, Daniele Rodolico, Galli Mattia, Burzotta Francesco, Rocco Vergallo, Carlo Trani, Nadia Aspromonte, Filippo Crea Tags: Research Letter Source Type: research

Heart failure management during the COVID ‐19 outbreak in Italy: a telemedicine experience from a heart failure university tertiary referral centre
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Andrea Salzano, Roberta D'Assante, Francesca M. Stagnaro, Valeria Valente, Giulia Crisci, Federica Giardino, Michele Arcopinto, Eduardo Bossone, Alberto M. Marra, Antonio Cittadini Tags: Research Letter Source Type: research

Contemporary survival trends and aetiological characterization in non ‐ischaemic dilated cardiomyopathy
AbstractAimContemporary survival trends in dilated cardiomyopathy (DCM) are largely unknown. The aim of this study is to investigate clinical descriptors, survival trends and the prognostic impact of aetiological characterization in DCM patients.Methods and resultsDilated cardiomyopathy patients were consecutively enrolled and divided into four groups according to the period of enrolment (1978 –1984; 1985–1994; 1995–2004; and 2005–2015). A subset of patients with DCM of specific aetiology, enrolled from 2005 to 2015, was also analysed. Over a mean follow‐up of 12 ± 8 ye...
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Marco Merlo, Antonio Cannat à, Carola Pio Loco, Davide Stolfo, Giulia Barbati, Jessica Artico, Piero Gentile, Valerio De Paris, Federica Ramani, Massimo Zecchin, Marta Gigli, Bruno Pinamonti, Renata Korcova, Andrea Di Lenarda, Mauro Giacca, Tags: Research Article Source Type: research

Characterization of the inflammatory ‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatment of the disease
AbstractAccumulating evidence points to the existence of an inflammatory ‐metabolic phenotype of heart failure with a preserved ejection fraction (HFpEF), which is characterized by biomarkers of inflammation, an expanded epicardial adipose tissue mass, microvascular endothelial dysfunction, normal‐to‐mildly increased left ventricular volumes and systolic blood pres sures, and possibly, altered activity of adipocyte‐associated inflammatory mediators. A broad range of adipogenic metabolic and systemic inflammatory disorders – e.g. obesity, diabetes and metabolic syndrome as well as rheumatoid arthriti...
Source: European Journal of Heart Failure - June 26, 2020 Category: Cardiology Authors: Milton Packer, Carolyn S.P. Lam, Lars H. Lund, Mathew S. Maurer, Barry A. Borlaug Tags: Review Source Type: research